Search results
Results From The WOW.Com Content Network
Knoll Pharmaceuticals. Knoll Pharmaceuticals was a drug development company founded by Albert Knoll and Hans Knoll in Germany in 1886. The company was taken over by German BASF in 1975, which sold it to Abbott Laboratories on 30 June 2002 for $6.9 billion. [1] [2]
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Green Oaks, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. [2] The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total ...
Health care mainstay Abbott Labs sure hasn't had a quiet 2012. Between the patent cliff, the fiscal cliff, and more, it's been an eventful year for the medical sector as a whole. Abbott's year ...
Abbott has a debt-to-equity ratio of 68% and an interest coverage ratio of 14 times. 4. Growth A large dividend is nice; a large growing dividend is even better. To support a growing dividend, we ...
There were cheers for joy when Abbott Labs announced that it would split itself into two entities -- separating the device and diagnostics businesses from its pharmaceutical operation. Investors ...
Abbott Laboratories v. Gardner, 387 U.S. 136 (1967), was a case heard before the United States Supreme Court.The Court held that drug companies were not prohibited by the ripeness doctrine from challenging a U.S. Food and Drug Administration (FDA) regulation requiring a prescription drug's generic name to appear on all related printed materials.
The case is Noriega v Abbott Laboratories, U.S. District Court, Southern District of New York, No. 23-04014. (Reporting by Jonathan Stempel in New York; Editing by Will Dunham)